(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.77%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.64%.
Passage Bio's earnings in 2026 is -$37,676,000.On average, 5 Wall Street analysts forecast PASG's earnings for 2026 to be -$34,148,421, with the lowest PASG earnings forecast at -$44,262,646, and the highest PASG earnings forecast at -$28,966,524. On average, 5 Wall Street analysts forecast PASG's earnings for 2027 to be -$31,727,166, with the lowest PASG earnings forecast at -$36,309,201, and the highest PASG earnings forecast at -$27,989,746.
In 2028, PASG is forecast to generate -$29,840,332 in earnings, with the lowest earnings forecast at -$29,456,036 and the highest earnings forecast at -$29,875,938.